A 12-year-old boy diagnosed with a rare muscle-wasting condition has recently begun receiving a life-altering NHS treatment following a period of uncertainty for his family. Ben Clarke, who has Duchenne Muscular Dystrophy (DMD), a severe genetic disorder that primarily affects boys, is one of many patients benefiting from givinostat after its approval for use in specific NHS Trusts.
Despite the positive development, Ben’s father, Alex Clarke, emphasizes that the battle is ongoing, cautioning that other families may face tragic outcomes before obtaining similar opportunities. Alex described the joy on Ben’s face upon learning about the drug’s approval, highlighting his son’s happiness and improved well-being since starting the treatment.
Givinostat, designed to slow disease progression and preserve muscle function, has been sanctioned only for ambulant boys at this stage. Ben was diagnosed with DMD at the age of four, prompting his family’s relentless pursuit of the treatment, ultimately leading to his access to medication.
While the family celebrates this milestone, Alex underscores the need to extend approval to non-ambulant boys, acknowledging the challenges faced by families in accessing the treatment. He stresses the importance of timely access to therapies for all affected individuals, emphasizing the impact of delays on their quality of life.
Alex’s advocacy echoes the sentiments of many families grappling with the complexities of accessing essential treatments. The journey towards equitable access to life-changing medications continues, ensuring that all individuals affected by rare conditions have a fighting chance for a better future.
